Skip to main content
Equibles
PLSH logo

PLSH · Panacea Life Sciences Holdings, Inc.

Track PLSH — free

Use PLSH with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PLSH.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.08 At close · Nov 10
Rebalance outlook locked
Going-concern doubt — flagged May 6, 2024

Substantial doubt about the company's ability to continue as a going concern.

“These factors raise substantial doubt about the Company's ability to continue as a going concern for a period of 12 months from the issuance date of this report. Management cannot provide assurance that the Company will ultimately achieve profitable operations or become cash flow positive or raise additional debt and/or equity capital.”
View the 10-Q filed May 6, 2024
Market Cap
$1.46M
Shares
17.65M
Volume · Nov 10 1123 Avg daily vol (3M) 6856

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.08 Open$0.08 Day$0.08–0.08 52W close$0.03–0.14 Avg vol 30d8K Short int8K · 0.0% of shares · 4.2d Short vol100% DataApr 2022–Nov 2026 Filing10-Q · May 6

Latest documents

2024
Apr 1
Annual report 10-K FY2023, ended Dec 31
Annual report for FY2023
Revenue $2.38M ▲ 46.6% Net loss $8.02M Diluted EPS -$0.48
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$2.76M
Trailing 12 months
Net income (TTM)
−$7.67M
Trailing 12 months
Revenue growth YoY
+55.9%
Year over year
Operating margin
-192.2%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+10.2%
Year over year · more shares
Price change (1Y)
+38.0%
Trailing year
Short interest
—
Latest settlement
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Strong Sentiment Bullish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 18.7 · elevated Equity put/call 0.72
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +45%
above
Price vs 50-day avg −4%
below
RSI (14) 52
neutral
MACD trend Negative
52-week position 50%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return −10%
trailing
6-month return +10%
trailing
YTD return +66%
this year
Relative strength +9%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $0 › 200d $0 — 50d above 200d
Institutional flow Flat
0% holders QoQ
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.05% of shares out · ▼ -0.1% MoM · 4.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
1 holders — 13F breadth
Fundamentals
Strong
Revenue growth +12%
Y/Y
Gross margin 49%
expanding
EPS growth +23%
Y/Y
Free cash flow $-1.6M
Balance sheet $251.1K
net debt
Quant / Vol
risk profile
Very High
Volatility 448%
annualized · 1-yr
Max drawdown −86%
past year
ATR 15.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
1 · 5 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+45% Bullish
Price vs 50-day avg
−4% Neutral
RSI (14)
52 Neutral
MACD trend
Negative Bearish
52-week position
50% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 1 of 6
Trend (MA cross) No cross
50d $0 › 200d $0 — 50d above 200d
Institutional flow Flat
0% holders QoQ
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.05% of shares out · ▼ -0.1% MoM · 4.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
1 holders — 13F breadth
Price context
position in its 52-week range
Range low $0 Now $0 · 50% Range high $0
vs 200-day avg +45% vs 50-day avg -4%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
PLSH
Panacea Life Sciences Holdings, Inc.
this stock
$1.46M +65.6% +11.7% — 0.0%
TAK
Takeda Pharmaceutical Co Ltd
 $67.48B +35.5% — — 0.1%
GALDY
Galderma Group AG
 $54.01B +11.7% — — 0.0%
TEVA
Teva Pharmaceutical Industries Ltd
 $50.93B +39.9% +4.3% 99.2 2.4%
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
 $40.66B — — — 0.1%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
1
% held
0.0%
Net QoQ
-735 sh
Top holder
Castleview Partners, LLC
Held Float
View
Short & Settlement
Short Interest Falling
Shares short
8.4K
Days to cover
4.2d
Change
-10 sh
View
Short Volume
Short vol %
100%
As of
Nov 4, 2026
Short Total
View
Fails to Deliver
FTD shares
3.4K
Value
$376
As of
Jul 8, 2026
View
Off-Exchange
Off-exchange %
100.0%
Week of
Oct 5, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$2.4M
Net income (FY)
$-8.0M
EPS diluted
$-0.48
View
Filings
SEC Filings
Latest
8-K
Filed
May 16, 2024
This year
0
View
Exempt Offerings
Offering
$5.0M
Filed
Feb 18, 2021
View

Performance

5D 20D 120D MTD YTD
PLSH +3.8% -10.3% +10.4% +0.0% +65.6%
SPY -0.6% -3.6% +1.2% -0.8% +10.0%
vs SPY +4.4% -6.7% +9.2% +0.8% +55.6%
Key facts CIK 1552189 CUSIP 69810P109 Visit website